Medical tests

Specimen Validity Testing Market Worth 1.49 Billion USD by 2023

Retrieved on: 
Thursday, May 17, 2018
Chemistry, Medical tests, Biology, Doping in sport, Drug control law, Drug test, Tests, Workplace, Nature, Assay, Reagent

According to a new market research report "Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%.

Key Points: 
  • According to a new market research report "Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023", published by MarketsandMarkets, the market is expected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%.
  • Growth in the drug & alcohol treatment and increase in workplace drug testing are the factors driving the growth of the Specimen Validity Testing Market.
  • Based on product, the Specimen Validity Testing Market is segmented into reagents, calibrators, and controls; assay kits; and disposables.
  • Based on type, the Specimen Validity Testing Market is segmented into laboratory testing and rapid/POC testing.

Neuroscience Antibodies and Assays Market Worth 4.18 Billion USD by 2023

Retrieved on: 
Wednesday, May 16, 2018
Medicine, Biology, Clinical medicine, Biotechnology, Medical tests, Immunoassay, Biochemistry, Immunochemistry, Molecular diagnostics, Antibody, Neuroscience, Assay

Growth in Neuroscience Antibodies and Assays Market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries.

Key Points: 
  • Growth in Neuroscience Antibodies and Assays Market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries.
  • Based on technology, the Neuroscience Antibodies and Assays Market are segmented into immunoassays/immunochemistry, molecular diagnostics, clinical chemistry, and other technologies.
  • In 2018, immunoassays/immunochemistry segment is expected to account for the largest share of the neuroscience antibodies and assays market.
  • Based on application, the Neuroscience Antibodies and Assays Market are segmented into research, drug discovery and development, and in vitro diagnostics.

Omega Laboratories Announces Groundbreaking 17-panel Hair Drug Test to Help Organizations Tackle Drug Epidemic

Retrieved on: 
Tuesday, May 15, 2018
Medical tests, Doping in sport, Drug control law, Medicine, Drug test, Tests, Workplace, Clinical medicine, Hair analysis, Health

MOGADORE, Ohio, May 15, 2018 /PRNewswire/ --Omega Laboratories is proud to introduce the Omega Hair 17-panel drug test, the most comprehensive hair test ever offered.

Key Points: 
  • MOGADORE, Ohio, May 15, 2018 /PRNewswire/ --Omega Laboratories is proud to introduce the Omega Hair 17-panel drug test, the most comprehensive hair test ever offered.
  • This new panel uses a proprietary screening method which allows Omega to screen for 17+ drug classes using only 12.5 mg of hair.
  • About Omega Laboratories, Inc. - Omega Laboratories, an industry leader in advanced specimen drug testing, has been working for years to move hair testing forward.
  • Omega Laboratories headquartered in Mogadore, Ohio is a state-of-the-art facility providing laboratory-based hair and oral fluid testing for drugs of abuse to over 6,000 clients worldwide.

Ortho Clinical Diagnostics and Sentinel Diagnostics Agree to Development, Wide-Range C-Reactive Protein Assay

Retrieved on: 
Tuesday, May 15, 2018
Medicine, Clinical medicine, Medical tests, Ortho Clinical Diagnostics, Immunologic tests, Laboratory techniques, Ortho, C-reactive protein, In vitro

RARITAN, N.J., May 15, 2018 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced an international distribution and co-promotion agreement with Sentinel Diagnostics, to provide a wide-range C-Reactive Protein assay, the CRP Ultra (MP) Assay.

Key Points: 
  • RARITAN, N.J., May 15, 2018 /PRNewswire/ --Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced an international distribution and co-promotion agreement with Sentinel Diagnostics, to provide a wide-range C-Reactive Protein assay, the CRP Ultra (MP) Assay.
  • In line with Ortho's commitment to providing a broad range of options and formulations for customer tests, the CRP Ultra assay provides a third C-Reactive Protein testing option for Ortho customers.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.
  • This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward.

Infectious Disease Diagnostic Market Demand, Business Opportunity and Future Growth Analysis Report: Radiant Insights, Inc.

Retrieved on: 
Monday, May 14, 2018
Medical tests, Biology, Medicine, Biotechnology, Molecular diagnostics, Infection, Health, Pathology, National Microbiology Laboratory

Infectious disease diagnostics resembles the process of determining the existence of foreign antigen by having a set of diagnostic tools.

Key Points: 
  • Infectious disease diagnostics resembles the process of determining the existence of foreign antigen by having a set of diagnostic tools.
  • Market driving factors responsible for the growth of infectious disease diagnostic market include growing incidences of infectious disease, emphasis on advanced molecular techniques in underdeveloped regions.
  • Based on test type, the infectious disease diagnostic market is segmented into laboratory tests, imaging tests and biopsies.
  • Based on technology, the infectious disease diagnostic market is segmented into molecular diagnostics and traditional diagnostics.

SQI Diagnostics and Microdrop Launch Revolutionary Disease Awareness Tests for Direct-to-Consumer Market

Retrieved on: 
Thursday, May 10, 2018
Clinical Laboratory Improvement Amendments, Healthcare in the United States, Health, Medical tests, Biotechnology companies

Microdrop now represents the 4th new SQI customers that brings a recurring revenue opportunity from diagnostic testing in the customer's CLIA laboratory.

Key Points: 
  • Microdrop now represents the 4th new SQI customers that brings a recurring revenue opportunity from diagnostic testing in the customer's CLIA laboratory.
  • According to the University of Chicago Celiac Disease Center: "Celiac Disease affects at least 3 million Americans.
  • Following the launch and roll-out of these first two testing products over the next two quarters, the companies will work together to launch new tests for the rapidly growing direct-to-consumer market for other diseases.
  • SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics.

Ortho Clinical Diagnostics in India Recognized as a 'Great Place to Work'

Retrieved on: 
Thursday, May 10, 2018
Medical tests, Ortho Clinical Diagnostics, Ortho

RARITAN, N.J. and MUMBAI, India, May 10, 2018 /PRNewswire/ --Ortho Clinical Diagnostics India has been certified as a Great Place to Work by the Great Place to Work Institute, India.

Key Points: 
  • RARITAN, N.J. and MUMBAI, India, May 10, 2018 /PRNewswire/ --Ortho Clinical Diagnostics India has been certified as a Great Place to Work by the Great Place to Work Institute, India.
  • "India is a key growth market for Ortho," said Alex Socarrs, Ortho's chief commercial officer.
  • More recently, the India-based Economic Times recognized Ortho as one of the Best Asian Healthcare Brands for 2017 .
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.

Computed Tomography (CT) Systems - Medical Devices Pipeline Assessment, 2018

Retrieved on: 
Wednesday, May 9, 2018
Medical tests, Medicine, Medical imaging, CT scan, Multidimensional signal processing, Tomography

NEW YORK, May 9, 2018 /PRNewswire/ -- Computed Tomography (CT) Systems - Medical Devices Pipeline Assessment, 2018

Key Points: 
  • NEW YORK, May 9, 2018 /PRNewswire/ -- Computed Tomography (CT) Systems - Medical Devices Pipeline Assessment, 2018
    GlobalData's Medical Devices sector report, "Computed Tomography (CT) Systems - Medical Devices Pipeline Assessment, 2018" provides an overview of Computed Tomography (CT) Systems currently in pipeline stage.
  • The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.The report reviews major players involved in the pipeline product development.
  • It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Computed Tomography (CT) Systems pipeline products.
  • - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    - Recent developments in the segment / industry.

ECRI Institute Reveals Important Differences in Prenatal Genetic Tests

Retrieved on: 
Wednesday, May 9, 2018
Medicine, Genetics, Biology, Microarrays, Medical genetics, Medical tests, Sequenom, Natera, Prenatal testing, ECRI Institute, Genetic counseling, Illumina

On May 22, 2018, analysts from ECRI Institute's independent genetic test information service ECRIgene will host an educational webinar to address issues surrounding tests by Roche Sequencing (Harmony Prenatal Test), Sequenom (MaterniT 21 Plus), Natera Inc. (Panorama), and Illumina (verifi Prenatal Test).

Key Points: 
  • On May 22, 2018, analysts from ECRI Institute's independent genetic test information service ECRIgene will host an educational webinar to address issues surrounding tests by Roche Sequencing (Harmony Prenatal Test), Sequenom (MaterniT 21 Plus), Natera Inc. (Panorama), and Illumina (verifi Prenatal Test).
  • The program, Noninvasive Prenatal Tests: Bringing Evidence into the Equation , is intended to help healthcare professionals, including genetic counselors, understand how to differentiate between noninvasive prenatal tests and standard-of-care tests.
  • For more information or to register, please visit www.ecri.org/NIPTwebinar or contact ECRI Institute by telephone at (610) 825-6000, ext.
  • As pioneers in this science for 50 years, ECRI Institute marries experience and independence with the objectivity of evidence-based research.

Three Day Point-of-Care Diagnostics & Global Health Conference: San Diego, CA, United States, October 1st-3rd, 2018

Retrieved on: 
Tuesday, May 8, 2018
Health, Medicine, POC, Point of care, Medical tests

The "Point-of-Care Diagnostics & Global Health 2018" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Point-of-Care Diagnostics & Global Health 2018" conference has been added to ResearchAndMarkets.com's offering.
  • This conference will provide an overview of the point-of-care (POC) testing landscape, from novel technologies to regulatory approval.
  • Also, we frame the role of POC testing in the expanding Global Health field and highlight opportunities existing in many parts of the world.
  • This conference covers POC Detection, POC Diagnostics and POC-based Treatment Options as part of the Comprehensive Coverage of this Expanding Field.